Deals Of The Week: Algeta/Ablynx, Pfizer/Cystic Fibrosis Foundation, Paladin/Ativa
Executive Summary
Tryptophan-induced somnolence may be a side effect of Thanksgiving dinner, but the business week leading into Thanksgiving was not sleepy, as we were not short of deals to review.
You may also be interested in...
BioMimetic Amends Augment Bone Graft PMA, Expects Approval By 2014
BioMimetic Therapeutics submits PMA amendment for its Augment bone graft device to address questions raised by FDA in a “not approvable” letter disclosed in January.
DSM Makes Waves In Omega-3 Fish Oil With Ocean Nutrition Pick-Up
The Dutch ingredients company hopes to expand Ocean Nutrition Canada into a global omega-3 fish oil supplier for foods and supplements, as well as a source for pharma ingredients. With expiring IP on the Martek algal DHA process, DSM could be seeking a hedge.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.